AbbVie price target lowered to $233 from $248 at BofA

BofA lowered the firm’s price target connected AbbVie (ABBV) to $233 from $248 and keeps a Neutral standing connected the shares. The firm, which sees “a comparatively cleanable setup” for maturation astatine the precocious extremity of the adjacent radical being balanced by a premium aggregate and constricted late-stage pipeline catalysts, is shifting its valuation ground to its FY27 estimates.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level information and almighty investing tools designed to assistance you marque smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation truthful your portfolio is ever positioned for maximum potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected ABBV:

Disclaimer & DisclosureReport an Issue

• AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

• AbbVie’s New Study connected Parkinson’s Treatment: What Investors Need to Know

• AbbVie’s Pediatric Kidney Disease Study Update: Implications for Investors

• AbbVie’s Venetoclax Study for AML: Key Insights for Investors

• AbbVie’s Phase III CLL Study: A Potential Game-Changer successful Cancer Treatment